A Novel Influenza A (H1N1) Vaccine in Various Age Groups

Zhu, Fengcai; Wang, Hua; Fang, Han-Hua; Yang, Jian Guo; Lin, Xiao Jun; Liang, Xiaofeng; Zhang, Xuefeng; Pan, Hongxing; Meng, Fanjuan; Hu, Yue; Li, Wendong; Li, Changgui; Li, Wei; Zhang, Xiang; Hu, Jin Mei; Peng, Wei; Yang, Bao Ping; Xi, Peng; Wang, Huaqing; Zheng, Jingshan

doi:10.1056/nejmoa0908535

Cited by 317 publications

(292 citation statements)

References 9 publications

Supporting

Mentioning

244

Contrasting

Unclassified

Order By: Relevance

“…These data corroborate that, as reported in children under 12 years of age, 23 ESRD and dialysis patients require two doses for adequate protection.…”

Section: Discussionsupporting

confidence: 91%

Influence of renal replacement therapy on immune response after one and two doses of the A(H1N1) pdm09 vaccine

Quintana

Serra

Molina-Llauradó

et al. 2012

Influenza Resp Viruses

View full text Add to dashboard Cite

Please cite this paper as: Quintana et al. (2012) Influence of renal replacement therapy on immune response after one and two doses of the A(H1N1) pdm09 vaccine. Influenza and Other Respiratory Viruses DOI: 10.1111/irv.12024. Background Patients with end‐stage renal disease have a reduced response to vaccination because of the general suppression of the immune system associated with uraemia. Objectives We evaluated the immune response and differential factors in the immunogenecity to an adjuvanted A(H1N1) pdm09 vaccine (Pandemrix®) in four populations of renal patients after one and two doses of vaccine. Patients Methods 151 patients were included in this study: 58 chronic haemodialysis patients, 52 renal allograft recipients, 14 peritoneal dialysis patients and 27 patients with advanced chronic kidney disease in preparation for kidney replacement therapy. Influenza‐specific antibody levels were measured by monitoring A(H1N1) pdm09 titres using a haemagglutination inhibition assay. Results The seroconversion rate at 42 days after two vaccine doses was 80% in the haemodialysis group, 64·9% in the renal allograft recipients group, 100% in the advanced chronic kidney disease group and 71·4% in the peritoneal dialysis group (P = 0·041). Conclusions Immune response to two doses of the influenza A H1N1 vaccine is dissimilar in the four renal conditions, confirming that seroprotection in pre‐dialysis, haemodialysis and peritoneal dialysis is similar to that in the general population vaccinated with one dose. In contrast, renal transplant recipients with good allograft function showed inadequate protection and triple immunosuppressive therapy including calcineurin inhibitors, mycophenolate and steroids negatively influenced seroconversion after vaccination in renal recipients.

show abstract

“…These data corroborate that, as reported in children under 12 years of age, 23 ESRD and dialysis patients require two doses for adequate protection.…”

Section: Discussionsupporting

confidence: 91%

Influence of renal replacement therapy on immune response after one and two doses of the A(H1N1) pdm09 vaccine

Quintana

Serra

Molina-Llauradó

et al. 2012

Influenza Resp Viruses

View full text Add to dashboard Cite

show abstract

“…However, the sero-protection proportion among subjects (73%) was slightly lower than reported proportions in healthy adults (79-95%). 7,9,10 In particular, the proportion among patients >65-y-old (58%) was rather lower than the reported proportions in age-matched healthy adults (79-80%). 9,10 No serious adverse effects were observed and all reported adverse reactions were self-limited.…”

Section: Discussionmentioning

confidence: 60%

“…We found that the following [10][11][12] and seasonal influenza vaccine. [13][14][15] Compromised nutritional status [16][17][18] and decreased T-cell activity [18][19][20] could be contributing factors for that finding.…”

Section: Discussionmentioning

confidence: 78%

“…Previous studies [25][26][27][28][29] have suggested that 2 doses of vaccine are required to elicit a protective immune response in populations that are immunologically naïve to a new influenza strain. One study 10 reported that immune responses in the elderly could be substantially boosted by a second dose of vaccine-among subjects ≥61-y-old who received a 15-μg dose of unadjuvanted A(H1N1)pdm09 vaccine, the seroprotection proportion was 79.1% at 21 d after the first dose, and 93.3% at 14 d after the second dose (35 d after first dose). According to our data, the proportion at 21 d after vaccination among diabetic patients >65-y-old was substantially lower (58%) and a second dose might improve immunogenicity.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Immunogenicity of influenza A(H1N1)pdm09 vaccine in patients with diabetes mellitus

Egawa

Ohfuji

Fukushima

et al. 2014

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

“…vaccine being well tolerated and immunogenic (Nicholson et al, 2009), while other groups found that H1N1 split virus (detergent-disrupted virion) vaccine formulations containing alum were less immunogenic than formulations without adjuvant when given i.m. (Zhu et al, 2009). Chitosan has shown promising results in i.n.…”

Section: Introductionmentioning

confidence: 99%

A lack of antibody formation against inactivated influenza virus after aerosol vaccination in presence or absence of adjuvantia

Geus

Haarlem

Poetri

et al. 2011

Veterinary Immunology and Immunopathology

View full text Add to dashboard Cite

a b s t r a c tIn the poultry industry, infections with avian influenza virus (AIV) can result in significant economic losses. The risk and the size of an outbreak might be restricted by vaccination of poultry. A vaccine that would be used for rapid intervention during an outbreak should be safe to use, highly effective after a single administration and be suitable for mass application. A vaccine that could be applied by spray or aerosol would be suitable for mass application, but respiratory applied inactivated influenza is poorly immunogenic and needs to be adjuvanted. We chose aluminum OH, chitosan, cholera toxin B subunit (CT-B), and Stimune as adjuvant for an aerosolized vaccine with inactivated H9N2. Each adjuvant was tested in two doses. None of the adjuvanted vaccines induced AIV-specific antibodies after single vaccination, measured 1 and 3 weeks after vaccination by aerosol, in contrast to the intramuscularly applied vaccine. The aerosolized vaccine did enter the chickens' respiratory tract as CT-B-specific serum antibodies were detected after 1 week in chickens vaccinated with the CT-B-adjuvanted vaccine. Chickens showed no adverse effects after the aerosol vaccination based on weight gain and clinical signs. The failure to detect AIV-specific antibodies might be due to the concentration of the inactivated virus.

show abstract

A Novel Influenza A (H1N1) Vaccine in Various Age Groups

Cited by 317 publications

References 9 publications

Influence of renal replacement therapy on immune response after one and two doses of the A(H1N1) pdm09 vaccine

Influence of renal replacement therapy on immune response after one and two doses of the A(H1N1) pdm09 vaccine

Immunogenicity of influenza A(H1N1)pdm09 vaccine in patients with diabetes mellitus

A lack of antibody formation against inactivated influenza virus after aerosol vaccination in presence or absence of adjuvantia

Contact Info

Product

Resources

About